Primary diffuse large B cell lymphoma arising from a leiomyoma of the uterine corpus

Diagnostic Pathology
Lianhua ZhaoHualiang Xiao

Abstract

Primary diffuse large B cell lymphoma (DLBCL) of the uterus is rare, and primary DLBCL arising from a uterine leiomyoma (collision tumor) has not been reported in the literature. We describe the clinical, histological, immunohistochemical, and molecular features of primary DLBCL arising from a leiomyoma in the uterine corpus. A 73-year-old female patient had a uterine mass for 23 years. An ultrasound scan revealed marked enlargement of the uterus, measuring 18.2 × 13 × 16.3 cm, with a 17.6 × 10.9 × 11.6 cm hypoechoic mass in the uterine corpus. The tumors consisted of medium- to large-sized cells exhibiting a diffuse pattern of growth with a well-circumscribed leiomyoma. The neoplastic cells strongly expressed CD79α, CD20 and PAX5. Molecular analyses indicated clonal B-cell receptor gene rearrangement. To the best of our knowledge, no previous cases of primary DLBCL arising from a leiomyoma have been reported. It is necessary to differentiate a diagnosis of primary DLBCL arising from a leiomyoma from that of leiomyoma with florid reactive lymphocytic infiltration (lymphoma-like lesion). Careful analysis of clinical, histological, immunophenotypic, and genetic features is required to establish the correct diagnosis.

References

Jan 1, 1989·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·J A FerryR E Scully
Feb 5, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·R VangM Deavers
Apr 17, 2004·Pathology International·Seung Sam PaikSam Hyun Cho
Jul 4, 2006·American Journal of Obstetrics and Gynecology·Roopa HariprasadShridhar Papaiah

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
hysterectomy

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.